

Table 1. Population characteristics and outcome in case-control study.

GROUPS	Participants	G0	G01	G1	G2	G3	G4	G5
All	1060	111	43	76	472	42	312	4
%	100	10.69	4,05	7,17	44,52	3,96	29,43	0,37
2020	499 (47,07%)	51	14	30	215	7	179	3
2021	561 (52,92%)	60	29	46	257	35	133	1
COVID-19 test		no	no	yes	no	yes	yes	2x yes
negative	671 (63,3%)	111	43	0	471	35	11	0
positive	389 (36,69%)	0	0	76	1	7	301	4
COVID-19 response								
no	662 (62,45%)	111	43	0	470	35	2	0
>30 days	18 (1,69%)	0	0	13	1	2	1	2
60-90 days	81 (7,64%)	0	0	18	0	3	58	2
>180 days	299 (28,2%)	0	0	45	1	0	251	0
COVID-19 Vaccinated		no	no	no	yes	yes	yes	yes
no	232 (21,88%)	111	43	76	0	0	0	0
yes	828 (78,11%)	0	0	0	472	24	312	4
COMIRNATY	788 (74,34%)	0	0	0	472	0	312	4
Astra Zeneka	21 (1,98%)	0	0	0	0	21	0	0
Moderna	19 (1,79%)	0	0	0	0	19	0	0
Johnson&Johnson	2 (0,19%)	0	0	0	0	2	0	0
Vaccination response								
no	748 (70,56%)	111	43	76	288	31	197	2
<14 days	58 (5,47%)	0	0	0	28	4	26	0
14-90 days	183 (17,3%)	0	0	0	111	7	64	1
>90 days	71 (6,69%)	0	0	0	45	0	25	1
Ig G cut-off		1060						
<1,0	685 (64,62%)	111	19	41	420	27	192	3
>0,2	375 (35,37%)	0	43	42	103	19	167	1
>1,0	247 (23,30%)	0	24	35	52	15	120	1
Ig M cut-off		1060						
<1,0	879 (82,92%)	103	33	65	397	36	242	3
>1,0	181 (17,07%)	8	10	11	75	6	70	1
S-RBD cut-off		546						
<1,0	81 (7,64%)	31	2	6	31	4	7	0
>1,0	465 (43,86%)	20	22	33	220	21	147	2
> 50	295 (27,83%)	0	3	11	154	8	117	2
> 100	246 (23,20%)	0	3	8	126	6	101	2
> 500	57 (5,38%)	0	0	1	14	4	36	2
> 1000	38 (3,58%)	0	0	0	10	3	23	2